Screening for Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the most serious complications of chronic liver disease and is the third most lethal cancer worldwide. Symptoms emerge very late in the course of its natural history with an attendant poor outcome. Screening is of paramount importance in a successful strategy to tr...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
SAGE-Hindawi Access to Research
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199100/ |
| id |
pubmed-3199100 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-31991002011-10-25 Screening for Hepatocellular Carcinoma Lui, Hock-Foong Review Article Hepatocellular carcinoma is one of the most serious complications of chronic liver disease and is the third most lethal cancer worldwide. Symptoms emerge very late in the course of its natural history with an attendant poor outcome. Screening is of paramount importance in a successful strategy to treat hepatocellular carcinoma. A successful screening program rests the availability of an at-risk population, reliable diagnostics tests that are able to diagnose a condition at a stage where effective, and relatively simple and acceptable treatments are available. In hepatocellular carcinoma, all patients with liver cirrhosis or chronic hepatitis B virus infection are at risk. Six monthly ultrasound and alpha-foetoprotein determination form the backbone of the screening program. Newer modalities and tests show promise but have not supplanted the standard tests. SAGE-Hindawi Access to Research 2011 2011-10-17 /pmc/articles/PMC3199100/ /pubmed/22028976 http://dx.doi.org/10.4061/2011/363151 Text en Copyright © 2011 Hock-Foong Lui. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Lui, Hock-Foong |
| spellingShingle |
Lui, Hock-Foong Screening for Hepatocellular Carcinoma |
| author_facet |
Lui, Hock-Foong |
| author_sort |
Lui, Hock-Foong |
| title |
Screening for Hepatocellular Carcinoma |
| title_short |
Screening for Hepatocellular Carcinoma |
| title_full |
Screening for Hepatocellular Carcinoma |
| title_fullStr |
Screening for Hepatocellular Carcinoma |
| title_full_unstemmed |
Screening for Hepatocellular Carcinoma |
| title_sort |
screening for hepatocellular carcinoma |
| description |
Hepatocellular carcinoma is one of the most serious complications of chronic liver disease and is the third most lethal cancer worldwide. Symptoms emerge very late in the course of its natural history with an attendant poor outcome. Screening is of paramount importance in a successful strategy to treat hepatocellular carcinoma. A successful screening program rests the availability of an at-risk population, reliable diagnostics tests that are able to diagnose a condition at a stage where effective, and relatively simple and acceptable treatments are available. In hepatocellular carcinoma, all patients with liver cirrhosis or chronic hepatitis B virus infection are at risk. Six monthly ultrasound and alpha-foetoprotein determination form the backbone of the screening program. Newer modalities and tests show promise but have not supplanted the standard tests. |
| publisher |
SAGE-Hindawi Access to Research |
| publishDate |
2011 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199100/ |
| _version_ |
1611482722461548544 |